{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:36:43Z","timestamp":1785760603321,"version":"3.56.0"},"reference-count":126,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Women's Dermatology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ijwd.2021.08.013","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T15:55:56Z","timestamp":1630598156000},"page":"588-599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"PA","title":["Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management"],"prefix":"10.1097","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7910-7908","authenticated-orcid":false,"given":"Asli","family":"Bilgic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salih","family":"Ozcobanoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcin Cansu","family":"Bozca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7049-0170","authenticated-orcid":false,"given":"Erkan","family":"Alpsoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"4","key":"10.1016\/j.ijwd.2021.08.013_bib0001","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11239-012-0743-5","article-title":"Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: Treatment with low-molecular-weight heparin","volume":"34","author":"Abou Rahal","year":"2012","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"10.1016\/j.ijwd.2021.08.013_bib0002","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2133.1999.02622.x","article-title":"Livedoid vasculitis: A manifestation of the antiphospholipid syndrome?","volume":"140","author":"Acland","year":"1999","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ijwd.2021.08.013_bib0003","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11239-011-0556-y","article-title":"Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy","volume":"32","author":"Agirbasli","year":"2011","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"10.1016\/j.ijwd.2021.08.013_bib0004","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaad.2013.07.019","article-title":"Livedoid vasculopathy: An in-depth analysis using a modified Delphi approach","volume":"69","author":"Alavi","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1540-9740.2006.04541.x","article-title":"Idiopathic atrophie blanche","volume":"5","author":"Amato","year":"2006","journal-title":"Skinmed"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0006","first-page":"404","article-title":"Use of intravenous immunoglobulin in livedo vasculitis","volume":"18","author":"Amital","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0008","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/mnfr.201200108","article-title":"Response of serum and red blood cell folate concentrations to folic acid supplementation depends on methylenetetrahydrofolate reductase C677T genotype: Results from a crossover trial","volume":"57","author":"Anderson","year":"2013","journal-title":"Mol Nutr Food Res"},{"issue":"1","key":"10.1016\/j.ijwd.2021.08.013_bib0009","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2340\/00015555-0760","article-title":"Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G\/4G) and prothrombin G20210A heterozygosity: Response to t-PA therapy","volume":"90","author":"Antunes","year":"2010","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.ijwd.2021.08.013_bib0010","first-page":"35","article-title":"Livedoid vasculopathy successfully treated with hyperbaric oxygen","volume":"43","author":"Banham","year":"2013","journal-title":"Diving Hyperb Med"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0011","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/archderm.1967.01610050011002","article-title":"Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis","volume":"96","author":"Bard","year":"1967","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2021.08.013_bib0013","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.mjafi.2012.01.002","article-title":"Livedoid vasculopathy managed with hyperbaric oxygen therapy","volume":"68","author":"Bhutani","year":"2012","journal-title":"Med J Armed Forces India"},{"issue":"2","key":"10.1016\/j.ijwd.2021.08.013_bib0014","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0190-9622(08)81156-5","article-title":"Sulfasalazine in atrophie blanche","volume":"28","author":"Bisalbutra","year":"1993","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2021.08.013_bib0015","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1590\/s1679-45082011rc1676","article-title":"Livedoid vasculopathy: fast involution after anticoagulant and hyperbaric oxygen therapy","volume":"9","author":"Bollmann","year":"2011","journal-title":"Einstein (Sao Paulo)"},{"issue":"9","key":"10.1016\/j.ijwd.2021.08.013_bib0016","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1365-4632.2012.05826.x","article-title":"Intravenous immunoglobulins in difficult-to-treat ulcerated livedoid vasculopathy: Five cases and a literature review","volume":"52","author":"Bounfour","year":"2013","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.ijwd.2021.08.013_bib0017","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/archderm.142.1.75","article-title":"Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia","volume":"142","author":"Browning","year":"2006","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2021.08.013_bib0018","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-4632.2007.03229.x","article-title":"Livedoid vasculopathy and hypercoagulability in a patient with primary Sjogren's syndrome","volume":"46","author":"Cardoso","year":"2007","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.ijwd.2021.08.013_bib0019","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1365-4632.2012.05786.x","article-title":"Livedoid vasculopathy (LV) associated with sticky platelets syndrome type 3 (SPS type 3) and enhanced activity of plasminogen activator inhibitor (PAI-1) anomalies","volume":"53","author":"Castillo-Mart\u00ednez","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2147\/JPR.S133462","article-title":"Treatment application of rivaroxaban in Chinese patients with livedoid vasculopathy","volume":"10","author":"Chen","year":"2017","journal-title":"J Pain Res"},{"issue":"2","key":"10.1016\/j.ijwd.2021.08.013_bib0021","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0190-9622(99)70189-1","article-title":"Livedo reticularis and livedoid vasculitis responding to PUVA therapy","volume":"40","author":"Choi","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.ijwd.2021.08.013_bib0022","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1590\/S0365-05962011000500015","article-title":"Livedoid vasculopathy: An intringuing cutaneous disease","volume":"86","author":"Criado","year":"2011","journal-title":"An Bras Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2021.08.013_bib0023","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1534734613502049","article-title":"Unilateral livedoid vasculopathy associated with involutional phase of cutaneous infantile hemangioma: The connection to coagulation disorders","volume":"12","author":"Criado","year":"2013","journal-title":"Int J Low Extrem Wounds"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0024","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/ced.12157","article-title":"Direct immunofluorescence findings and thrombophilic factors in livedoid vasculopathy: how do they correlate?","volume":"39","author":"Criado","year":"2014","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2021.08.013_bib0025","doi-asserted-by":"crossref","first-page":"e14810","DOI":"10.1111\/dth.14810","article-title":"Livedoid vasculopathy in 75 Brazilian patients in a single-center institution: Clinical, histopathological and therapy evaluation","volume":"34","author":"Criado","year":"2021","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.ijwd.2021.08.013_bib0026","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.2196\/resprot.3640","article-title":"A phase II multicenter trial with rivaroxaban in the treatment of livedoid vasculopathy assessing pain on a visual analog scale","volume":"3","author":"Drabik","year":"2014","journal-title":"JMIR Res Protoc"},{"issue":"11","key":"10.1016\/j.ijwd.2021.08.013_bib0027","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/archderm.142.11.1466","article-title":"Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G\/4G) treated successfully with tissue plasminogen activator","volume":"142","author":"Deng","year":"2006","journal-title":"Arch Dermatol"},{"issue":"11","key":"10.1016\/j.ijwd.2021.08.013_bib0028","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/j.1468-3083.2010.03646.x","article-title":"Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs\u2013A prospective study","volume":"24","author":"Di Giacomo","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.ijwd.2021.08.013_bib0029","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1111\/jdv.14404","article-title":"Prevention of livedoid vasculopathy recurrence by prolonged administration of rivaroxaban","volume":"31","author":"Drerup","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.ijwd.2021.08.013_bib0030","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0190-9622(82)70123-9","article-title":"Antiplatelet therapy in atrophie blanche and livedo vasculitis","volume":"7","author":"Drucker","year":"1982","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2021.08.013_bib0031","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1742-481X.2011.00882.x","article-title":"Livedoid vasculopathy associated with sickle cell trait: Significant improvement on aspirin treatment","volume":"9","author":"El Khoury","year":"2012","journal-title":"Int Wound J"},{"issue":"7","key":"10.1016\/j.ijwd.2021.08.013_bib0032","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2340\/00015555-2416","article-title":"Recalcitrant livedoid vasculopathy associated with hyperhomocysteinaemia responding to folic acid and vitamins B6\/B12 supplementation","volume":"96","author":"Errichetti","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.ijwd.2021.08.013_bib0033","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jdcr.2015.08.002","article-title":"Successful treatment of livedoid vasculopathy with rivaroxaban","volume":"1","author":"Evans","year":"2015","journal-title":"JAAD Case Rep"},{"issue":"5","key":"10.1016\/j.ijwd.2021.08.013_bib0034","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2340\/00015555-1711","article-title":"Livedoid vasculopathy: clinical features and treatment in 24 Chinese patients","volume":"94","author":"Feng","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0035","first-page":"323","article-title":"Hyperbaric medicine","volume":"22","author":"Fernandes","year":"2009","journal-title":"Acta Med Port"},{"issue":"8","key":"10.1016\/j.ijwd.2021.08.013_bib0036","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/archderm.140.8.1011","article-title":"Difficult management of livedoid vasculopathy","volume":"140","author":"Franc\u00e8s","year":"2004","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2021.08.013_bib0037","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/ijd.13997","article-title":"Alves Batista Morita TC, Cajas Garc\u00eda MS. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): Four case reports successfully treated with rivaroxaban","volume":"57","author":"Franco Marques","year":"2018","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2021.08.013_bib0038","doi-asserted-by":"crossref","DOI":"10.4322\/acr.2018.034","article-title":"Livedoid vasculopathy: A compelling diagnosis","volume":"8","author":"Freitas","year":"2018","journal-title":"Autops Case Rep"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0039","doi-asserted-by":"crossref","first-page":"400","DOI":"10.47102\/annals-acadmedsg.V41N9p400","article-title":"A ten-year retrospective study on livedo vasculopathy in Asian patients","volume":"41","author":"Gan","year":"2012","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0040","doi-asserted-by":"crossref","DOI":"10.1111\/iwj.13563","article-title":"Livedoid vasculopathy and its association with genetic variants: A systematic review","author":"Gao","year":"2021","journal-title":"Int Wound J"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0041","first-page":"1","article-title":"Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: A retrospective analysis","author":"Gao","year":"2020","journal-title":"J Dermatol Treat"},{"issue":"9","key":"10.1016\/j.ijwd.2021.08.013_bib0042","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2340\/00015555-2965","article-title":"Livedoid vasculopathy: A French observational study including therapeutic options","volume":"98","author":"Gardette","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.ijwd.2021.08.013_bib0043","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jaad.2019.07.112","article-title":"Retiform purpura: A diagnostic approach","volume":"82","author":"Georgesen","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.ijwd.2021.08.013_bib0044","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/archdermatol.2010.177","article-title":"Livedoid vasculopathy in a pediatric patient with elevated lipoprotein(a) levels: Prompt response to continuous low-molecular-weight heparin","volume":"146","author":"Goerge","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1529-8019.2012.01490.x","article-title":"Update of management of connective tissue diseases: Livedoid vasculopathy","volume":"25","author":"Gonzalez-Santiago","year":"2012","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0046","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/archderm.139.8.987","article-title":"Treatment of livedoid vasculopathy with low-molecular-weight heparin: Report of 2 cases","volume":"139","author":"Hairston","year":"2003","journal-title":"Arch Dermatol"},{"issue":"11","key":"10.1016\/j.ijwd.2021.08.013_bib0047","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archderm.142.11.1413","article-title":"Livedoid vasculopathy: Further evidence for procoagulant pathogenesis","volume":"142","author":"Hairston","year":"2006","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2021.08.013_bib0048","first-page":"302","article-title":"Livedoid vasculopathy: Review of pathogenesis, clinical presentation, diagnostic workup, and treatment","volume":"90","author":"Haunson","year":"2012","journal-title":"Cutis"},{"issue":"6","key":"10.1016\/j.ijwd.2021.08.013_bib0049","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archderm.138.6.841","article-title":"Livedoid vasculitis with ulcerations: The role of antithrombin III deficiency and its therapeutic consequences","volume":"138","author":"Hegemann","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0050","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1055\/s-0037-1622240","article-title":"Therapeutic use of low molecular weight heparin for capillaritis alba","volume":"37","author":"Hesse","year":"2008","journal-title":"Phlebologie"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0051","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/archderm.1996.03890310027003","article-title":"Livedoid vasculitis. Response to low-dose danazol","volume":"132","author":"Hsiao","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0052","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000246113","article-title":"Low-dose danazol in the treatment of livedoid vasculitis","volume":"194","author":"Hsiao","year":"1997","journal-title":"Dermatology"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0053","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/DAD.0b013e3181b7bf90","article-title":"Distinct pattern of direct immunofluorescence in livedoid vasculopathy","volume":"32","author":"Hsiao","year":"2010","journal-title":"Am J Dermatopathol"},{"issue":"11","key":"10.1016\/j.ijwd.2021.08.013_bib0054","doi-asserted-by":"crossref","first-page":"e6284","DOI":"10.1097\/MD.0000000000006284","article-title":"Dermoscopic features of livedoid vasculopathy","volume":"96","author":"Hu","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.ijwd.2021.08.013_bib0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11239-008-0214-1","article-title":"Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity","volume":"26","author":"Irani-Hakime","year":"2008","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"10.1016\/j.ijwd.2021.08.013_bib0056","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/DAD.0b013e31819560aa","article-title":"Livedoid vasculopathy with underlying subcutaneous necrotizing venulitis in an asymptomatic hepatitis B virus carrier: Is livedoid vasculopathy a true nonvasculitic disorder?","volume":"31","author":"Ishibashi","year":"2009","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"10.1016\/j.ijwd.2021.08.013_bib0058","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ad.2017.07.015","article-title":"Treatment of livedoid vasculopathy with rivaroxaban: A potential use of new oral anticoagulants for dermatologists","volume":"109","author":"Jim\u00e9nez-Gallo","year":"2018","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"4","key":"10.1016\/j.ijwd.2021.08.013_bib0059","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1445-5994.1995.tb01909.x","article-title":"Dramatic response of livedoid vasculitis to tissue plasminogen activator (tPA)","volume":"25","author":"Johnson","year":"1995","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0060","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2133.2005.06843.x","article-title":"Livedoid vasculopathy: Long-term follow-up results following hyperbaric oxygen therapy","volume":"154","author":"Juan","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0061","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/09546630701670305","article-title":"A case of livedoid vasculopathy associated with factor V Leiden mutation: Successful treatment with oral warfarin","volume":"19","author":"Kavala","year":"2008","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"10.1016\/j.ijwd.2021.08.013_bib0062","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2133.2007.08143.x","article-title":"Therapeutic effect of lipoprostaglandin E1 on livedoid vasculitis associated with essential cryoglobulinaemia","volume":"157","author":"Kawakami","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0063","first-page":"22","article-title":"Livedoid thrombotic vasculopathy responding to doxycycline therapy","volume":"1","author":"Keller","year":"2008","journal-title":"J Clin Aesthet Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2021.08.013_bib0064","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/bjd.12100","article-title":"Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy","volume":"168","author":"Kerk","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0065","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1111\/j.1365-2230.2009.03541.x","article-title":"Livedoid vasculitis associated with a double heterozygous Factor V Leiden and prothrombin G20210A gene mutation","volume":"34","author":"Khenifer","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.ijwd.2021.08.013_bib0066","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/dth.12233","article-title":"Pulsed intravenous immunoglobulin therapy in refractory ulcerated livedoid vasculopathy: Seven cases and a literature review","volume":"28","author":"Kim","year":"2015","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0067","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0025-6196(12)60922-7","article-title":"Tissue plasminogen activator for treatment of livedoid vasculitis","volume":"67","author":"Klein","year":"1992","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0068","doi-asserted-by":"crossref","DOI":"10.1177\/12034754211003525","article-title":"Intravenous immunoglobulin therapy in livedoid vasculopathy: Retrospective observation of clinical outcome and patient's activity level","author":"Kofler","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0069","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaad.2004.05.003","article-title":"Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: An open trial evaluating 9 consecutive patients","volume":"51","author":"Kreuter","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.ijwd.2021.08.013_bib0070","doi-asserted-by":"crossref","DOI":"10.5070\/D3267049556","article-title":"Primary livedoid vasculopathy associated with mononeuritis multiplex","volume":"26","author":"Krueger","year":"2020","journal-title":"Dermatol Online J"},{"issue":"2","key":"10.1016\/j.ijwd.2021.08.013_bib0071","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jdcr.2017.09.003","article-title":"Ulcerative livedoid vasculopathy responding to clopidogrel","volume":"4","author":"Kunzler","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0072","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1365-4362.2001.01183.x","article-title":"Livedoid vasculitis responding to PUVA therapy","volume":"40","author":"Lee","year":"2001","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2021.08.013_bib0073","doi-asserted-by":"crossref","first-page":"835","DOI":"10.47102\/annals-acadmedsg.V32N6p835","article-title":"Clinical profile and treatment outcome of livedoid vasculitis: A case series","volume":"32","author":"Lee","year":"2003","journal-title":"Ann Acad Med Singap"},{"issue":"5","key":"10.1016\/j.ijwd.2021.08.013_bib0074","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/ced.12829","article-title":"Case series of recalcitrant livedoid vasculopathy treated with rivaroxaban","volume":"41","author":"Lee","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0075","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1111\/jdv.16129","article-title":"Livedoid vasculopathy in Koreans: Clinical features and response to rivaroxaban treatment","volume":"34","author":"Lee","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.ijwd.2021.08.013_bib0076","doi-asserted-by":"crossref","first-page":"544","DOI":"10.36849\/JDD.2020.4684","article-title":"Successful treatment of painful cutaneous vasculopathy with rivaroxaban in a patient with systemic lupus erythematosus","volume":"19","author":"Leisenring","year":"2020","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2021.08.013_bib0077","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bjd.19222","article-title":"Thrombotic occlusive vasculopathy in a skin biopsy from a livedoid lesion of a patient with COVID-19","volume":"183","author":"Llamas-Velasco","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2021.08.013_bib0078","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0248-8663(02)00611-2","article-title":"Livedoid vasculopathy with combined thrombophilia: Efficacy of iloprost","volume":"23","author":"Magy","year":"2002","journal-title":"Rev M\u00e9d Interne"},{"issue":"6","key":"10.1016\/j.ijwd.2021.08.013_bib0080","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/00015550310015455","article-title":"Widespread livedoid vasculopathy","volume":"83","author":"Marzano","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0081","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2230.1992.tb02522.x","article-title":"Livedo vasculitis: Vasculitis or thrombotic vasculopathy?","volume":"17","author":"McCalmont","year":"1992","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2021.08.013_bib0082","first-page":"159","article-title":"Livedoid vasculopathy. The role of hyperhomocysteinemia and its simple therapeutic consequences","volume":"16","author":"Meiss","year":"2006","journal-title":"Eur J Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2021.08.013_bib0083","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4103\/0378-6323.164217","article-title":"Cilostazol: A novel agent in recalcitrant livedoid vasculopathy","volume":"82","author":"Mendiratta","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"10.1016\/j.ijwd.2021.08.013_bib0084","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/jamadermatol.2017.4374","article-title":"Treatment for livedoid vasculopathy: A systematic review","volume":"154","author":"Micieli","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.ijwd.2021.08.013_bib0085","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/ced.13943","article-title":"Chronic leg ulcerations associated with livedoid vasculopathy successfully treated with rivaroxaban","volume":"45","author":"Miguel","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0086","first-page":"865","article-title":"Les atrophies cutanees syphilitiques","volume":"36","author":"Milian","year":"1929","journal-title":"Bull Soc Fr Dermatol Syph"},{"issue":"2","key":"10.1016\/j.ijwd.2021.08.013_bib0087","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1111\/j.1468-3083.2012.04480.x","article-title":"Treatment of livedoid vasculopathy with alprostadil (PGE-1): Case report and review of published literature","volume":"27","author":"Mofarrah","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.ijwd.2021.08.013_bib0089","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jaad.2014.05.039","article-title":"Efficacy of intravenous immunoglobulins in livedoid vasculopathy: Long-term follow-up of 11 patients","volume":"71","author":"Monshi","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2021.08.013_bib0090","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archderm.1995.01690140117029","article-title":"Failure of livedoid vasculitis to respond to tissue plasminogen activator","volume":"131","author":"Murrell","year":"1995","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2021.08.013_bib0091","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1684\/ejd.2011.1529","article-title":"Livedoid vasculopathy; favorable clinical response with low dose warfarin","volume":"21","author":"Nakamura","year":"2011","journal-title":"Eur J Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2021.08.013_bib0092","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/1346-8138.13652","article-title":"Livedoid vasculopathy and popliteal artery occlusion in a patient with protein S deficiency","volume":"44","author":"Nakayama","year":"2017","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.ijwd.2021.08.013_bib0093","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/archdermatol.2011.106","article-title":"Severe livedoid vasculopathy associated with antiphosphatidylserine-prothrombin complex antibody successfully treated with warfarin","volume":"147","author":"Noda","year":"2011","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2021.08.013_bib0094","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/ced.14464","article-title":"Direct immunofluorescence findings in livedoid vasculopathy: A 10-year study and literature review","volume":"46","author":"Nuttawong","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2021.08.013_bib0095","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2340\/00015555-0413","article-title":"A case of widespread livedoid vasculopathy with pain but no systemic symptoms","volume":"88","author":"Okada","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0096","first-page":"796","article-title":"Normal human polyspecific immunoglobulin G (intravenous immunoglobulin) modulates endothelial cell function in vitro","volume":"10","author":"Oravec","year":"1995","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.ijwd.2021.08.013_bib0097","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1346-8138.2009.00754.x","article-title":"Case of livedoid vasculopathy with peripheral neuropathy successfully treated with low-dose warfarin","volume":"37","author":"Osada","year":"2010","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2021.08.013_bib0098","doi-asserted-by":"crossref","first-page":"e13229","DOI":"10.1111\/dth.13229","article-title":"Intravenous immunoglobulin in resistant livedoid vasculopathy: Analysis of a case series","volume":"33","author":"Ozden","year":"2020","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.ijwd.2021.08.013_bib0099","first-page":"374","article-title":"Treatment of livedoid vasculopathy with short-cycle intravenous immunoglobulins","volume":"85","author":"Pitarch","year":"2005","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.ijwd.2021.08.013_bib0101","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0190-9622(86)80551-5","article-title":"Nifedipine treatment of idiopathic atrophie blanche","volume":"14","author":"Purcell","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0102","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1046\/j.1365-2133.2002.04755.x","article-title":"Response of livedoid vasculitis to intravenous immunoglobulin","volume":"147","author":"Ravat","year":"2002","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.ijwd.2021.08.013_bib0103","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4103\/0019-5154.159657","article-title":"Livedoid vasculopathy with hyperhomocysteinemia responding to hyperbaric oxygen therapy","volume":"60","author":"Ray","year":"2015","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0104","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF00320896","article-title":"Fibrinolysis induced by danazol","volume":"53","author":"Rizzo","year":"1986","journal-title":"Blut"},{"issue":"1","key":"10.1016\/j.ijwd.2021.08.013_bib0105","doi-asserted-by":"crossref","first-page":"e14569","DOI":"10.1111\/dth.14569","article-title":"Livedoid vasculopathy: Clinical course and long-term outcome in Asian patients with a review of the literature","volume":"34","author":"Rujitharanawong","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0106","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2133.1989.tb07771.x","article-title":"Chronic leg ulceration with livedoid vasculitis, and response to oral ketanserin","volume":"120","author":"Rustin","year":"1989","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.ijwd.2021.08.013_bib0107","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/archderm.1988.01670050028013","article-title":"Livedo vasculitis. Therapy with pentoxifylline","volume":"124","author":"Sams","year":"1988","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2021.08.013_bib0108","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijgo.2009.06.020","article-title":"Livedoid vasculopathy and pregnancy","volume":"107","author":"Sankar","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"10.1016\/j.ijwd.2021.08.013_bib0109","doi-asserted-by":"crossref","first-page":"508","DOI":"10.4103\/ijd.IJD_564_16","article-title":"Use of low-dose oral warfarin in three cases of livedoid vasculopathy","volume":"62","author":"Saoji","year":"2017","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0110","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/archderm.1971.04000210028005","article-title":"Immunofluorescence of cutaneous vasculitis associated with systemic disease","volume":"104","author":"Schroeter","year":"1971","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0111","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/archderm.1975.01630140046003","article-title":"Livedo vasculitis (the vasculitis of atrophie blanche). Immunohistopathologic study","volume":"111","author":"Schroeter","year":"1975","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0112","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1097\/CM9.0000000000000396","article-title":"Dermoscopy in China: Current status and future prospective","volume":"132","author":"Shen","year":"2019","journal-title":"Chin Med J"},{"issue":"6","key":"10.1016\/j.ijwd.2021.08.013_bib0113","doi-asserted-by":"crossref","first-page":"508","DOI":"10.5021\/ad.2020.32.6.508","article-title":"A case of livedoid vasculopathy successfully treated with sulodexide","volume":"32","author":"Song","year":"2020","journal-title":"Ann Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2021.08.013_bib0114","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000246335","article-title":"Successful treatment of livedo vasculitis with beraprost sodium: A possible mechanism of thrombomodulin upregulation","volume":"192","author":"Tsutsui","year":"1996","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.ijwd.2021.08.013_bib0115","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1590\/abd1806-4841.20132363","article-title":"Livedoid vasculopathy associated with peripheral neuropathy: A report of two cases","volume":"88","author":"Tubone","year":"2013","journal-title":"An Bras Dermatol"},{"issue":"10","key":"10.1016\/j.ijwd.2021.08.013_bib0116","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/archdermatol.2011.274","article-title":"Successful long-term use of intravenous immunoglobulin to treat livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity","volume":"147","author":"Tuchinda","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0117","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1600-0781.2005.00151.x","article-title":"Refractory livedoid vasculitis responding to PUVA: A report of four cases","volume":"21","author":"Tuchinda","year":"2005","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"5","key":"10.1016\/j.ijwd.2021.08.013_bib0118","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1111\/ijd.15423","article-title":"Recrudescence of livedoid vasculopathy induced by COVID-19","volume":"60","author":"Valentim","year":"2021","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0120","doi-asserted-by":"crossref","first-page":"478","DOI":"10.4103\/0378-6323.183635","article-title":"Livedoid vasculopathy: A review of pathogenesis and principles of management","volume":"82","author":"Vasudevan","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"10.1016\/j.ijwd.2021.08.013_bib0121","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.mjafi.2013.02.009","article-title":"Livedoid vasculopathy managed with hyperbaric oxygen therapy","volume":"69","author":"Verma","year":"2013","journal-title":"Med J Armed Forces India"},{"issue":"3","key":"10.1016\/j.ijwd.2021.08.013_bib0122","first-page":"273","article-title":"Livedoid vasculopathy\u2013A challenging disease","volume":"41","author":"Vieira","year":"2016","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0124","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2133.2003.05546.x","article-title":"Intractable livedoid vasculopathy successfully treated with hyperbaric oxygen","volume":"149","author":"Yang","year":"2003","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ijwd.2021.08.013_bib0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaad.2011.07.021","article-title":"Association between peripheral vascular endothelial dysfunction and livedoid vasculopathy","volume":"67","author":"Yang","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.ijwd.2021.08.013_bib0126","first-page":"e258","article-title":"Livedoid vasculopathy and its association with factor V Leiden mutation","volume":"53","author":"Yong","year":"2012","journal-title":"Singapore Med J"},{"issue":"11","key":"10.1016\/j.ijwd.2021.08.013_bib0127","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/ccr3.1803","article-title":"Systemic lupus erythematosus with refractory ulcerated livedoid vasculopathy: Successful treatment with intravenous immunoglobulin and warfarin","volume":"6","author":"Yoshioka","year":"2018","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0128","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1046\/j.1365-2133.1998.02541.x","article-title":"Livedoid vasculitis with anticardiolipin antibodies: Improvement with danazol","volume":"139","author":"Wakelin","year":"1998","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2021.08.013_bib0129","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1016\/S2352-3026(15)00251-3","article-title":"Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): A multicentre, single-arm, open-label, phase 2a, proof-of-concept trial","volume":"3","author":"Weishaupt","year":"2016","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.ijwd.2021.08.013_bib0130","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/jdv.15639","article-title":"Characteristics, risk factors and treatment reality in livedoid vasculopathy\u2013A multicentre analysis","volume":"33","author":"Weishaupt","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"17","key":"10.1016\/j.ijwd.2021.08.013_bib0131","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/CM9.0000000000001048","article-title":"Clinical and dermoscopic features of livedoid vasculopathy","volume":"33","author":"Wen","year":"2020","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"10.1016\/j.ijwd.2021.08.013_bib0132","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/bjd.13428","article-title":"Response of livedoid vasculopathy to rivaroxaban","volume":"172","author":"Winchester","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0133","first-page":"746","article-title":"Clinical studies of livedoid vasculitis (segmental hyalinizing vasculitis)","volume":"49","author":"Winkelmann","year":"1974","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijwd.2021.08.013_bib0134","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/ard.2007.083931","article-title":"Successful use of rituximab in a patient with recalcitrant livedoid vasculopathy","volume":"67","author":"Zeni","year":"2008","journal-title":"Ann Rheum Dis"}],"container-title":["International Journal of Women's Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352647521001064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352647521001064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T17:52:34Z","timestamp":1725731554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352647521001064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":126,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2352647521001064"],"URL":"https:\/\/doi.org\/10.1016\/j.ijwd.2021.08.013","relation":{},"ISSN":["2352-6475"],"issn-type":[{"value":"2352-6475","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management","name":"articletitle","label":"Article Title"},{"value":"International Journal of Women's Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijwd.2021.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc. on behalf of Women's Dermatologic Society.","name":"copyright","label":"Copyright"}]}}